Compounds > meglumine antimoniate
Page last updated: 2024-08-24

meglumine antimoniate and transforming growth factor beta

meglumine antimoniate has been researched along with transforming growth factor beta in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Craft, N; Da-Cruz, AM; de Oliveira, MP; de Oliveira-Neto, MP; Maretti-Mira, AC; Pirmez, C1
Calvi, SA; da Silva, LD; de Abreu, MM; de Assis Golim, M; de Campos Soares, ÂM; Fortaleza, CM; Gatto, M; Simão, JC; Tasca, KI1
Azevedo, EG; Caliari, MMV; Castro, RS; de Amorim, IFG; Demicheli, C; Frezard, FJG; Michalick, MSM; Mosser, DM; Pereira, RA; Pinheiro, LJ; Pinto, AJW; Silva, SM; Tafuri, WL1
Aflatoonian, MR; Bamorovat, M; Fekri, A; Heshmatkhah, A; Keyhani, A; Khosravi, A; Mostafavi, M; Naderi, A; Oliaee, RT; Parizi, MH; Sharifi, I; Varma, RS1

Other Studies

4 other study(ies) available for meglumine antimoniate and transforming growth factor beta

ArticleYear
Therapeutic failure in American cutaneous leishmaniasis is associated with gelatinase activity and cytokine expression.
    Clinical and experimental immunology, 2011, Volume: 163, Issue:2

    Topics: Adult; Antimony; Antiprotozoal Agents; Cytokines; Female; Humans; Interferon-gamma; Interleukin-10; Leishmaniasis, Cutaneous; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Regeneration; Skin; Transforming Growth Factor beta; Treatment Failure

2011
The involvement of TLR2 and TLR4 in cytokine and nitric oxide production in visceral leishmaniasis patients before and after treatment with anti-leishmanial drugs.
    PloS one, 2015, Volume: 10, Issue:2

    Topics: Adolescent; Adult; Antiprotozoal Agents; Cells, Cultured; Cytokines; Female; Humans; Interferon-gamma; Interleukin-10; Interleukin-17; Leishmaniasis, Visceral; Lymphocytes; Male; Meglumine; Meglumine Antimoniate; Monocytes; Nitric Oxide; Organometallic Compounds; Toll-Like Receptor 2; Toll-Like Receptor 4; Transforming Growth Factor beta; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult

2015
Hepatic fibropoiesis in dogs naturally infected with Leishmania (Leishmania) infantum treated with liposome-encapsulated meglumine antimoniate and allopurinol.
    Veterinary parasitology, 2018, Jan-30, Volume: 250

    Topics: Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Gene Expression Regulation; Leishmania infantum; Leishmaniasis, Visceral; Liposomes; Liver; Liver Cirrhosis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Random Allocation; Transforming Growth Factor beta; Vimentin

2018
A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models.
    Microbial pathogenesis, 2019, Volume: 128

    Topics: Adolescent; Adult; Aged; Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Child; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Female; Humans; Interleukin-10; Interleukin-12 Subunit p40; Leishmania tropica; Leishmaniasis, Cutaneous; Levamisole; Macrophages; Male; Meglumine Antimoniate; Mice; Middle Aged; Nitric Oxide Synthase Type II; Transforming Growth Factor beta; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult

2019